medigraphic.com
ISSN 1817-5996 (Electronic)

2012, Number 20

<< Back Next >>

Rev Cub de Reu 2012; 14 (20)

Descriptive study of clinical activity and diseases modifying anti rheumatic drugs treatment in RA patients in the Rheumatology Center

Prada HDM, Molinero RC, Martell SR, Gómez MJA, Guibert TM, Hernández CIM, Suarez MR, Gil AR

Language: Spanish
References: 28
Page:
PDF size: 273.94 Kb.


ABSTRACT

The frecuent and continual evaluation of inflammatory activity such as early treatment with diseases modifying anti rheumatic drugs (DMARDs) in rheumatoid arthritis patients contribute to achieve the therapeutic goal of remission or to keep the patient with the minimum inflammatory activity because there is no curative treatment nowadays so rheumatoid arthritis patients should receive periodic follow up.
Objective. To evaluate clinical behavior of rheumatoid arthritis and to describe diseases modifying anti rheumatic drugs treatment.
Methods. A descriptive and prospective study in 200 patients with rheumatoid arthritis was carried out from january 2011 to july 2011 in the Rheumatology Center at 10 de October Clinical Hospital .The clinical activity evaluation was performed using the DAS 28 index and functional capacity by HAQ-CU questionnaire .The diseases modifying anti rheumatic drugs treatment in the studied patients was described.
Results. Most patients were female 94.5 % with a mean age of 56 years, 41 % of patients were more than 10 years of disease ,middle value DAS 28 and HAQ-CU fixed with moderate clinical activity and disability. These values correlate proportionally and are statistically significant, p ‹ 0.001,Pearson 0.729. Most patients reported diseases modifying anti rheumatic drugs treatment, 53 % of patients used monotherapy mainly methotrexate, 34 % used combined therapy.
Conclusions. Clinical findings in our study were similar to international reports and national therapeutic guidelines fixed with international therapeutic guidelines for RA patients.


REFERENCES

  1. Blanco Francisco Javier, Ballina Javier, Carbonell Jordi, Martín-Mola Emilio, Tornero Jesús, Ramírez Esteban y Galván Jordi. Estudio descriptivo de la utilización de los FAMES en los pacientes con artritis reumatoide o artritis persistente que inician tratamiento farmacológico en España. (ESTUDIO FIRST). Reumatol Clin. 2011;7(2):88–93

  2. Lozano JA. Artritis reumatoide (I). Etiopatogenia, sintomatología, diagnóstico y pronóstico. [Accedido 8 Jun 2010]. Disponible en: http://external.doyma.es/pdf/4/4v20n08a13018371pdf001.pdf.

  3. Castañeda Santos; Navarro F; Fernández-Carballido C; Tornero C; Merced E; Corteguera M. Diferencias en el manejo de la artritis reumatoide precoz y establecida. Reumatol Clin. 2011; 7(3). Mayo – Junio 2011.

  4. Loza E, Calvo J, del Canto F, Alarcón GS. Artritis Reumatoide en Enfermedades Autoinmunes. 2006. Barcelona. Masson, 2006. 369-399

  5. First Latín American Position Paper on The Pharmacological Treatment of Rheumatoid Arthritis. Rheumatology. Volume 45. Supplement 2. June 2006.

  6. Pons-Estel B, Gladar. Cohorte latino americana de pacientes con artritis reumatoide de reciente comienzo (ARRC). Grupo latino americano de estudio de artritis reumatoide. Reumatología 2005; 21: 165.

  7. Soledad Quesada M, García Vargas M. Serie de actualización profesional. Artritis Reumatoide. Fisiopatología y Tratamiento., Centro Nacional de Información de Medicamentos. Instituto de Investigaciones Farmacéuticas. Facultad de Farmacias. Universidad de Costa Rica. Marzo 2004.

  8. Tornero Molina J, Sanmartí Sala R, Rodríguez Valverde V, Martín Mola E, Marenco de la Fuente JL, González Álvaro I, et-al. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin. 2010; 6:23-36.

  9. Díaz-Jouanen E et al. Recomendaciones para el tratamiento médico de la artritis reumatoide. Rev. invest Clin 2005; 57 (5): 735-755.

  10. Guía de Práctica Clínica para el Manejo de la Artritis Reumatoide (GUIPCAR) en España. Marzo de 2007. [Accedido 8 Jun 2010]. Disponible en: http://www.ser.es/practicaClinica/GUIPCAR_2007/Metodologia/Menu1_Metodologia.php

  11. Rockville, MD. La combinación de fármacos en muchos casos es una mejor estrategia para combatir la artritis reumatoide. Press Release, November 20, 2007. Agency for Healthcare Research and Quality,. http://www.ahrq.gov/news/press/pr2007/spdmardpr.htm

  12. Rau Herborn G. Benedit and risk of methotrexate treatment in rheumatoid arthritis. Methotrexate produces more sustained responses over time than other DMARDs, such as sulphasalazine, parenteral gold, and hydroxychloroquine. Clin exp Reumatol 2004; 22: 83-94.

  13. Massardo L. Artritis Reumatoide Temprana. Revista méd Chile. 136 (11) Santiago.2008: 1468-1475.

  14. Fries JF. Spitz P. Kraines, et al. Assessment of patient outcome in arthritis. Arthritis Rheum 1980; 23:137-45

  15. Revista Cubana de Reumatología. 2002. Volumen IV, Núm. 1; p 52

  16. Allaire, S., Wolfe, F., Niu, J. and LaValley, M. P, Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis: Recent data from a US national cohort. Arthritis & Rheumatism March 2009, 61: 321–328.

  17. Aktekin LA, Eser F, Baskan BM, Sivas F, Malhan M, Oksuz E, Bodur H. Disability of Arm Shoulder and Hand Questionnaire in rheumatoid arthritis patients: relationship with disease activity, HAQ, SF-36. Rheumatol Int 2011; 31:823–26.

  18. Ton E, Bakker MF, Verstappen SM, Ter Borg EJ, van Albada-Kuipers IA, Schenk Y et al. Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. J Rheumatol.2012 Jan; 39(1):22-7.

  19. Klarenbeek N B, Koevoets R, van der Heijde D M F M, Gerards A H, Wolde S ten, Kerstens P J S M et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011; 70:1815–1821.

  20. Castrejon I., Ortiz A.M., Garcia-Vicuna R., Lopez-Bote J.P., Hambría A., Carmona L., et-al. Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis?. Clin Exp Rheumatol. 2008; 26:769-75.

  21. Radovits B.J., Fransen J., Van Riel P.L., Laan R.F. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis. 2008; 67:1127-31.

  22. Ahlmen M., Svensson B., Albertsson K., Forslind K., Hafstrom I. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. Ann Rheum Dis. 2009.

  23. Leeb B.F., Haindl P.M., Maktari A., Nothnagl T., Rintelen B. Disease activity score-28 values differ considerably depending on patient's pain perception and sex. J Rheumatol. 2007; 34:2382-7.

  24. Vetter G, Geisslinger G, Tegeder I. Release of glutamate, nitric oxide and prostaglandin E2 and metabolic activity in the spinal cord of rats following peripheral nociceptive stimulation. Pain 2001; 92:213-218

  25. Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature review. Inflamm Allergy Drug Targets. 2010 Mar; 9(1):51-9. Pub Med

  26. Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, Singh G, Yamanaka H . Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. . Ann Rheum Dis. 2008 Aug; 67(8):1153-8.

  27. Smolen JS, Aletaha D, Mchold KP. Therapeutic strategies in early Rheumatoid Artritis. Best pract Res Clin Reumatol 2005; 19:163-77

  28. Blanco-Morales E.A. et al. Glucocorticoides en artritis reumatoide: ¿casi siempre o casi nunca? / Reumatol Clin. 2011;7(6):407–411.




2020     |     www.medigraphic.com